Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;14(4):433–447. doi: 10.1111/j.1750-3639.2004.tb00088.x

Apolipoprotein Aβ: Black Sheep in a Good Family

Anatol Kontush 1
PMCID: PMC8095840  PMID: 15605991

Abstract

Amyloid‐β (Aβ) has for a long time been thought to play a central role in the pathogenesis of Alzheimer disease (AD). Analysis of available data indicates that Aβ possesses properties of a metal‐binding apolipoprotein influencing lipid transport and metabolism. Protection of lipoproteins from oxidation by transition metals, synaptic activity and role in the acute phase response represent plausible physiological functions of Aβ. However, these important biochemical qualities which may critically influence the development of AD, have been largely ignored by mainstream AD researchers, making Aβ appear to be a “black sheep” in a “good apolipoprotein” family. New studies are needed to shed further light on the physiological role of Aβ in lipid metabolism in the brain.

Full Text

The Full Text of this article is available as a PDF (367.7 KB).

REFERENCES

  • 1. Molecular Modeling Database (MMDB). In, http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgiform&=6&db=tDopt=s&uid=7992.
  • 2. Webster's Online Dictionary. In, http://www.websters‐online‐dictionary.org/definition/english/ap/apolipoproteins.html.
  • 3. Andorn AC, Kalaria RN (2000) Factors Affecting Pro‐ and Anti‐Oxidant Properties of Fragments of the b‐Protein Precursor (bPP): Implication for Alzheimer's Disease. J Alzheimers Dis 2:69–78. [DOI] [PubMed] [Google Scholar]
  • 4. Arlt S, Finckh B, Beisiegel U, Kontush A (2000) Time‐course of oxidation of lipids in human cerebrospinal fluid in vitro. Free Radic Res 32:103–114. [DOI] [PubMed] [Google Scholar]
  • 5. Assmann G, Nofer JR (2003) Atheroprotective effects of high‐density lipoproteins. Annu Rev Med 54:321–341. [DOI] [PubMed] [Google Scholar]
  • 6. Atwood CS, Huang X, Khatri A, Scarpa RC, Kim YS, Moir RD, Tanzi RE, Roher AE, Bush AI (2000) Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol Biol 46:777–783. [PubMed] [Google Scholar]
  • 7. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273:12817–12826. [DOI] [PubMed] [Google Scholar]
  • 8. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN (2003) Amyloid‐beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid‐beta. Brain Res Rev 43:1–16. [DOI] [PubMed] [Google Scholar]
  • 9. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI (2004) Copper mediates dityrosine cross‐linking of Alzheimer's amyloid‐beta. Biochemistry 43:560–568. [DOI] [PubMed] [Google Scholar]
  • 10. Atwood CS, Robinson SR, Smith MA (2002) Amyloid‐beta: redox‐metal chelator and antioxidant. J Alzheimers Dis 4:203–214. [DOI] [PubMed] [Google Scholar]
  • 11. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI (2000) Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar‐affinity copper binding site on amyloid beta 1–42. J Neurochem 75:1219–1233. [DOI] [PubMed] [Google Scholar]
  • 12. Barter P, Kastelein J, Nunn A, Hobbs R (2003) High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168:195–211. [DOI] [PubMed] [Google Scholar]
  • 13. Bassett CN, Neely MD, Sidell KR, Markesbery WR, Swift LL, Montine TJ (1999) Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids 34:1273–1280. [DOI] [PubMed] [Google Scholar]
  • 14. Basun H, Forssell LG, Wetterberg L, Winblad B (1991) Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 3:231–258. [PubMed] [Google Scholar]
  • 15. Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Rev 27:119–142. [DOI] [PubMed] [Google Scholar]
  • 16. Beffert U, Poirier J (1998) ApoE associated with lipid has a reduced capacity to inhibit beta‐amyloid fibril formation. Neuroreport 9:3321–3323. [DOI] [PubMed] [Google Scholar]
  • 17. Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817–827. [DOI] [PubMed] [Google Scholar]
  • 18. Berndt C, Kontush A, Beisiegel U (1998) Neuronal cell cultures protect low density lipoprotein from oxidation. Neurobiol Aging 19:S284. [Google Scholar]
  • 19. Berthon G (2000) Does human betaA4 exert a protective function against oxidative stress in Alzheimer's disease Med Hypotheses 54:672–677. [DOI] [PubMed] [Google Scholar]
  • 20. Berthon G (1993) Is copper pro‐ or anti‐inflammatory? A reconciling view and a novel approach for the use of copper in the control of inflammation. Agents Actions 39:210–217. [DOI] [PubMed] [Google Scholar]
  • 21. Bjorkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24:806–815. [DOI] [PubMed] [Google Scholar]
  • 22. Blasko I, Grubeck‐Loebenstein B (2003) Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 20:101–113. [DOI] [PubMed] [Google Scholar]
  • 23. Blennow K, Vanmechelen E (1998) Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm Suppl 53:223–235. [DOI] [PubMed] [Google Scholar]
  • 24. Borghini I, Barja F, Pometta D, James RW (1995) Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta 1255:192–200. [DOI] [PubMed] [Google Scholar]
  • 25. Brasseur R, Pillot T, Lins L, Vandekerckhove J, Rosseneu M (1997) Peptides in membranes: tipping the balance of membrane stability. Trends Biochem Sci 22:167–171. [DOI] [PubMed] [Google Scholar]
  • 26. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K (2003) Co‐localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Mol Brain Res 110:119–125. [DOI] [PubMed] [Google Scholar]
  • 27. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA (1993) Generation of beta‐amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A 90:2092–2096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Bush AI (2000) Metals and neuroscience. Curr Opin Chem Biol 4:184–191. [DOI] [PubMed] [Google Scholar]
  • 29. Bush AI, Atwood CS, Goldstein LE, Huang X, Rogers J (2000) Could Abeta and AbetaPP be Antioxidants J Alzheimers Dis 2:83–84. [DOI] [PubMed] [Google Scholar]
  • 30. Butterfield DA (2004) Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 1000:1–7. [DOI] [PubMed] [Google Scholar]
  • 31. Butterfield DA, Bush AI (2004) Alzheimer's amyloid beta‐peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25:563–568. [DOI] [PubMed] [Google Scholar]
  • 32. Campbell A (2001) Beta ‐amyloid: friend or foe. Med Hypotheses 56:388–391. [DOI] [PubMed] [Google Scholar]
  • 33. Chacon MA, Barria MI, Soto C, Inestrosa NC (2004) Beta‐sheet breaker peptide prevents Abeta‐induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry 20:20. [DOI] [PubMed] [Google Scholar]
  • 34. Chan C‐W, Dharmarajan A, Atwood CS, Huang X, Tanzi RE, Bush AI, Martins RN (1999) Anti‐apoptotic action of Alzheimer Abeta. Alzheimer's Rep 2:1–6. [Google Scholar]
  • 35. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta‐peptide in human blood. Biochem Biophys Res Commun 213:96–103. [DOI] [PubMed] [Google Scholar]
  • 36. Chisolm GM, Steinberg D (2000) The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28:1815–1826. [DOI] [PubMed] [Google Scholar]
  • 37. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ (1998) Solution structure of amyloid beta‐peptide(1–40) in a water‐micelle environment. Is the membrane‐spanning domain where we think it is Biochemistry 37:11064–11077. [DOI] [PubMed] [Google Scholar]
  • 38. Cornett CR, Markesbery WR, Ehmann WD (1998) Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19:339–345. [PubMed] [Google Scholar]
  • 39. Coskun PE, Beal MF, Wallace DC (2004) Alzheimer's brains harbor somatic mtDNA control‐region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A 101:10726–10731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, Picone D (2002) Solution structure of the Alzheimer amyloid beta‐peptide (1–42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 269:5642–5648. [DOI] [PubMed] [Google Scholar]
  • 41. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI (2000) Evidence that the beta‐amyloid plaques of Alzheimer's disease represent the redox‐silencing and entombment of abeta by zinc. J Biol Chem 275:19439–19442. [DOI] [PubMed] [Google Scholar]
  • 42. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ (2001) Alzheimer's disease amyloid‐beta binds copper and zinc to generate an allosterically ordered membrane‐penetrating structure containing superoxide dismutase‐like subunits. J Biol Chem 276:20466–20473. [DOI] [PubMed] [Google Scholar]
  • 43. Danik M, Champagne D, Petit‐Turcotte C, Beffert U, Poirier J (1999) Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit Rev Neurobiol 13:357–407. [DOI] [PubMed] [Google Scholar]
  • 44. Davies CA, Mann DM, Sumpter PQ, Yates PO (1987) A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 78:151–164. [DOI] [PubMed] [Google Scholar]
  • 45. De Felice FG, Ferreira ST (2002) Beta‐amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol 22:545–563. [DOI] [PubMed] [Google Scholar]
  • 46. Deibel MA, Ehmann WD, Markesbery WR (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 143:137–142. [DOI] [PubMed] [Google Scholar]
  • 47. DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, Sullivan PM, Fagan AM, Han X, Holtzman DM (2001) Purification and characterization of astrocyte‐secreted apolipoprotein E and J‐containing lipoproteins from wild‐type and human apoE transgenic mice. Neurochem Int 39:415–425. [DOI] [PubMed] [Google Scholar]
  • 48. Demeester N, Castro G, Desrumaux C, De Geitere C, Fruchart JC, Santens P, Mulleners E, Engelborghs S, De Deyn PP, Vandekerckhove J, Rosseneu M, Labeur C (2000) Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J Lipid Res 41:963–974. [PubMed] [Google Scholar]
  • 49. Dietschy JM, Turley SD (2004) Thematic review series: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45:1375–1397. [DOI] [PubMed] [Google Scholar]
  • 50. Dumery L, Bourdel F, Soussan Y, Fialkowsky A, Viale S, Nicolas P, Reboud‐Ravaux M (2001) beta‐Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease. Pathol Biol (Paris) 49:72–85. [DOI] [PubMed] [Google Scholar]
  • 51. Esteban JA (2004) Living with the enemy: a physiological role for the beta‐amyloid peptide. Trends Neurosci 27:1–3. [DOI] [PubMed] [Google Scholar]
  • 52. Fagan AM, Bu G, Sun Y, Daugherty A, Holtzman DM (1996) Apolipoprotein E‐containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor‐related protein. J Biol Chem 271:30121–30125. [DOI] [PubMed] [Google Scholar]
  • 53. Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA, LaDu MJ (1999) Unique lipoproteins secreted by primary astrocytes from wild type, apoE (‐/‐), and human apoE transgenic mice. J Biol Chem 274:30001–30007. [DOI] [PubMed] [Google Scholar]
  • 54. Finefrock AE, Bush AI, Doraiswamy PM (2003) Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 51:1143–1148. [DOI] [PubMed] [Google Scholar]
  • 55. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK (2000) Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 28:1735–1744. [DOI] [PubMed] [Google Scholar]
  • 56. Frank PG, Marcel YL (2000) Apolipoprotein A‐I: structure‐function relationships. J Lipid Res 41:853–872. [PubMed] [Google Scholar]
  • 57. Frederickson CJ, Bush AI (2001) Synaptically released zinc: physiological functions and pathological effects. Biometals 14:353–366. [DOI] [PubMed] [Google Scholar]
  • 58. Frederikse PH, Garland D, Zigler JS, Jr. , Piatigorsky J (1996) Oxidative stress increases production of beta‐amyloid precursor protein and beta‐amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem 271:10169–10174. [DOI] [PubMed] [Google Scholar]
  • 59. Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T (1999) Primary cultures of neuronal and non‐neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. Neuroreport 10:2965–2969. [DOI] [PubMed] [Google Scholar]
  • 60. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269:13623–13628. [PubMed] [Google Scholar]
  • 61. Gentleman SM, Greenberg BD, Savage MJ, Noori M, Newman SJ, Roberts GW, Griffin WS, Graham DI (1997) A beta 42 is the predominant form of amyloid beta‐protein in the brains of short‐term survivors of head injury. Neuroreport 8:1519–1522. [DOI] [PubMed] [Google Scholar]
  • 62. Ghiso J, Matsubara E, Koudinov A, Choi Miura NH, Tomita M, Wisniewski T, Frangione B (1993) The cerebrospinal‐fluid soluble form of Alzheimer's amyloid beta is complexed to SP‐40, 40 (apolipoprotein J), an inhibitor of the complement membrane‐attack complex. Biochem J 293:27–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Gong JS, Sawamura N, Zou K, Sakai J, Yanagisawa K, Michikawa M (2002) Amyloid beta‐protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J Neurosci Res 70:438–446. [DOI] [PubMed] [Google Scholar]
  • 64. Haas C, Schlossmacher MG, Hung AY, Vigo‐Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ (1992) Amyloid beta‐peptide is produced by cultured cells during normal metabolism. Nature 359:322–325. [DOI] [PubMed] [Google Scholar]
  • 65. Han SH, Hulette C, Saunders AM, Einstein G, Pericak‐Vance M, Strittmatter WJ, Roses AD, Schmechel DE (1994) Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age‐matched controls. Exp Neurol 128:13–26. [DOI] [PubMed] [Google Scholar]
  • 66. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20:154–159. [DOI] [PubMed] [Google Scholar]
  • 67. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353–356. [DOI] [PubMed] [Google Scholar]
  • 68. Hartter DE, Barnea A (1988) Evidence for release of copper in the brain: depolarization‐induced release of newly taken‐up 67copper. Synapse 2:412–415. [DOI] [PubMed] [Google Scholar]
  • 69. Hershey CO, Hershey LA, Varnes A, Vibhakar SD, Lavin P, Strain WH (1983) Cerebrospinal fluid trace element content in dementia: clinical, radiologic, and pathologic correlations. Neurology 33:1350–1353. [DOI] [PubMed] [Google Scholar]
  • 70. Hopt A, Korte S, Fink H, Panne U, Niessner R, Jahn R, Kretzschmar H, Herms J (2003) Methods for studying synaptosomal copper release. J Neurosci Methods 128:159–172. [DOI] [PubMed] [Google Scholar]
  • 71. Hoss W, Formaniak M (1980) Enhancement of synaptic vesicle attachment to the plasma membrane fraction by copper. Neurochem Res 5:795–803. [DOI] [PubMed] [Google Scholar]
  • 72. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:7609–7616. [DOI] [PubMed] [Google Scholar]
  • 73. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI (1999) Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell‐free hydrogen peroxide production and metal reduction. J Biol Chem 274:37111–37116. [DOI] [PubMed] [Google Scholar]
  • 74. Illingworth DR, Glover J (1971) The composition of lipids in cerebrospinal fluid of children and adults. J Neurochem 18:769–776. [DOI] [PubMed] [Google Scholar]
  • 75. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053–7059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Ito J, Zhang LY, Asai M, Yokoyama S (1999) Differential generation of high‐density lipoprotein by endogenous and exogenous apolipoproteins in cultured fetal rat astrocytes. J Neurochem 72:2362–2369. [DOI] [PubMed] [Google Scholar]
  • 77. Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ (2004) Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging 25:619–627. [DOI] [PubMed] [Google Scholar]
  • 78. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima‐Morishima M, Lee HJ, Hama E, Sekine‐Aizawa Y, Saido TC (2000) Identification of the major Abeta1–42‐degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6:143–150. [DOI] [PubMed] [Google Scholar]
  • 79. Jendroska K, Poewe W, Daniel SE, Pluess J, Iwerssen‐Schmidt H, Paulsen J, Barthel S, Schelosky L, Cervos‐Navarro J, DeArmond SJ (1995) Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol (Berl) 90:461–466. [DOI] [PubMed] [Google Scholar]
  • 80. Jonas A (2000) Lecithin cholesterol acyltransferase. Biochim Biophys Acta 1529:245–256. [DOI] [PubMed] [Google Scholar]
  • 81. Kahle PJ, De Strooper B (2003) Attack on amyloid. EMBO Rep 4:747–751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925–937. [DOI] [PubMed] [Google Scholar]
  • 83. Kardos J, Kovacs I, Hajos F, Kalman M, Simonyi M (1989) Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability. Neurosci Lett 103:139–144. [DOI] [PubMed] [Google Scholar]
  • 84. Kay AD, Day SP, Kerr M, Nicoll JA, Packard CJ, Caslake MJ (2003) Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury. J Neurotrauma 20:717–723. [DOI] [PubMed] [Google Scholar]
  • 85. Kay AD, Day SP, Nicoll JA, Packard CJ, Caslake MJ (2003) Remodelling of cerebrospinal fluid lipoproteins after subarachnoid hemorrhage. Atherosclerosis 170:141–146. [DOI] [PubMed] [Google Scholar]
  • 86. Keller JN, Hanni KB, Markesbery WR (1999) Oxidized low‐density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. J Neurochem 72:2601–2609. [DOI] [PubMed] [Google Scholar]
  • 87. Kindy MS, Yu J, Guo JT, Zhu H (1999) Apolipoprotein Serum Amyloid A in Alzheimer's Disease. J Alzheimers Dis 1:155–167. [DOI] [PubMed] [Google Scholar]
  • 88. Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, Buhmann C, Beisiegel U (2001) Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 42:1143–1151. [PubMed] [Google Scholar]
  • 89. Kontush A (2001) Alzheimer's amyloid‐beta as a preventive antioxidant for brain lipoproteins. Cell Mol Neurobiol 21:299–315. [DOI] [PubMed] [Google Scholar]
  • 90. Kontush A (2001) Amyloid‐beta: an antioxidant that becomes a pro‐oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 31:1120–1131. [DOI] [PubMed] [Google Scholar]
  • 91. Kontush A, Atwood CS (2004) Amyloid‐beta: phylogenesis of a chameleon. Brain Res Rev 46:118–120. [DOI] [PubMed] [Google Scholar]
  • 92. Kontush A, Berndt C, Weber W, Akopyan V, Arlt S, Schippling S, Beisiegel U (2001) Amyloid‐beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 30:119–128. [DOI] [PubMed] [Google Scholar]
  • 93. Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23:1881–1888. [DOI] [PubMed] [Google Scholar]
  • 94. Kontush A, Donarski N, Beisiegel U (2001) Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid‐beta content. Free Radic Res 35:507–517. [DOI] [PubMed] [Google Scholar]
  • 95. Kontush A, Mann U, Arlt S, Ujeyl A, Luhrs C, Muller‐Thomsen T, Beisiegel U (2001) Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic Biol Med 31:345–354. [DOI] [PubMed] [Google Scholar]
  • 96. Koo EH, Park L, Selkoe DJ (1993) Amyloid beta‐protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci U S A 90:4748–4752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Koudinov A, Matsubara E, Frangione B, Ghiso J (1994) The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 205:1164–1171. [DOI] [PubMed] [Google Scholar]
  • 98. Koudinov AR, Berezov TT, Koudinova NV (2001) The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology Neurosci Lett 314:115–118. [DOI] [PubMed] [Google Scholar]
  • 99. Koudinov AR, Berezov TT, Kumar A, Koudinova NV (1998) Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 270:75–84. [DOI] [PubMed] [Google Scholar]
  • 100. Koudinov AR, Koudinova NV (1997) Alzheimer's soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Cell Biol Int 21:265–271. [DOI] [PubMed] [Google Scholar]
  • 101. Koudinov AR, Koudinova NV (2003) Cholesterol, synaptic function and Alzheimer's disease. Pharmacopsychiatry 36:S107–112. [DOI] [PubMed] [Google Scholar]
  • 102. Koudinov AR, Koudinova NV (2001)Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15:1858–1860. [DOI] [PubMed] [Google Scholar]
  • 103. Koudinov AR, Koudinova NV, Berezov TT, Ivanov YD (1999) HDL phospholipid: a natural inhibitor of Alzheimer's amyloid beta‐fibrillogenesis Clin Chem Lab Med 37:993–994. [DOI] [PubMed] [Google Scholar]
  • 104. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J (1996) Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 223:592–597. [DOI] [PubMed] [Google Scholar]
  • 105. Koudinova NV (2003) Alzheimer's amyloid beta oligomers and lipoprotein apoAbeta: mistaken identity is possible. Bioessays 25:1024; author reply 1025. [DOI] [PubMed] [Google Scholar]
  • 106. Kunitake ST, Kane JP (1982) Factors affecting the integrity of high density lipoproteins in the ultracentrifuge. J Lipid Res 23:936–940. [PubMed] [Google Scholar]
  • 107. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE (1998) Elevated low‐density lipoprotein in Alzheimer's disease correlates with brain abeta 1–42 levels. Biochem Biophys Res Commun 252:711–715. [DOI] [PubMed] [Google Scholar]
  • 108. Kuo YM, Emmerling MR, Vigo‐Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water‐soluble Abeta (N‐40, N‐42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077–4081. [DOI] [PubMed] [Google Scholar]
  • 109. LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM (1998) Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 70:2070–2081. [DOI] [PubMed] [Google Scholar]
  • 110. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT (1995) Purification of apolipoprotein E attenuates isoform‐specific binding to beta‐amyloid. J Biol Chem 270:9039–9042. [DOI] [PubMed] [Google Scholar]
  • 111. Le Goff W, Guerin M, Chapman MJ (2004) Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 101:17–38. [DOI] [PubMed] [Google Scholar]
  • 112. LeBlanc A (1995) Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci 15:7837–7846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. LeBlanc AC, Xue R, Gambetti P (1996) Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia. J Neurochem 66:2300–2310. [DOI] [PubMed] [Google Scholar]
  • 114. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA (2004) Challenging the amyloid cascade hypothesis: senile plaques and amyloid‐beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 1019:1–4. [DOI] [PubMed] [Google Scholar]
  • 115. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender‐disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A 99:7705–7710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Lin WR, Wozniak MA, Cooper RJ, Wilcock GK, Itzhaki RF (2002) Herpesviruses in brain and Alzheimer's disease. J Pathol 197:395–402. [DOI] [PubMed] [Google Scholar]
  • 117. Lin WR, Wozniak MA, Wilcock GK, Itzhaki RF (2002) Cytomegalovirus is present in a very high proportion of brains from vascular dementia patients. Neurobiol Dis 9:82–87. [DOI] [PubMed] [Google Scholar]
  • 118. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM (2004) Chlamydia pneumoniae induces Alzheimer‐like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 25:419–429. [DOI] [PubMed] [Google Scholar]
  • 119. Liu ST, Howlett G, Barrow CJ (1999) Histidine‐13 is a crucial residue in the zinc ion‐induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry 38:9373–9378. [DOI] [PubMed] [Google Scholar]
  • 120. Loeffler DA, DeMaggio AJ, Juneau PL, Brick‐man CM, Mashour GA, Finkelman JH, Pomara N, LeWitt PA (1994) Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis Assoc Disord 8:190–197. [DOI] [PubMed] [Google Scholar]
  • 121. Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, Brickman CM, Brewer GJ, Dick RD, Troyer MD, Kanaley L (1996) Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res 738:265–274. [DOI] [PubMed] [Google Scholar]
  • 122. Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid‐reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45:1594–1601. [DOI] [PubMed] [Google Scholar]
  • 123. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158:47–52. [DOI] [PubMed] [Google Scholar]
  • 124. Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187–194. [DOI] [PubMed] [Google Scholar]
  • 125. Lovstad RA (1987) Copper catalyzed oxidation of ascorbate (vitamin C). Inhibitory effect of catalase, superoxide dismutase, serum proteins (ceruloplasmin, albumin, apotransferrin) and amino acids. Int J Biochem 19:309–313. [DOI] [PubMed] [Google Scholar]
  • 126. Lusis AJ (2000) Atherosclerosis. Nature 407:233–241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127. Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ (2004) ApoE and Abeta1–42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci 23:235–246. [DOI] [PubMed] [Google Scholar]
  • 128. Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89:169–179. [DOI] [PubMed] [Google Scholar]
  • 129. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134–147. [DOI] [PubMed] [Google Scholar]
  • 130. Markesbery WR, Lovell MA (1998) Four‐hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33–36. [DOI] [PubMed] [Google Scholar]
  • 131. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M (1999) Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45:537–541. [PubMed] [Google Scholar]
  • 132. Matsubara E, Sekijima Y, Tokuda T, Urakami K, Amari M, Shizuka‐Ikeda M, Tomidokoro Y, Ikeda M, Kawarabayashi T, Harigaya Y, Ikeda S, Murakami T, Abe K, Otomo E, Hirai S, Frangione B, Ghiso J, Shoji M (2004) Soluble Abeta homeostasis in AD and DS: impairment of anti‐amyloidogenic protection by lipoproteins. Neurobiol Aging 25:833–841. [DOI] [PubMed] [Google Scholar]
  • 133. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J (1996) Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 316:671–679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia‐derived cholesterol. Science 294:1354–1357. [DOI] [PubMed] [Google Scholar]
  • 135. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX (2002) Overexpression of Alzheimer's disease amyloid‐beta opposes the age‐dependent elevations of brain copper and iron. J Biol Chem 277:44670–44676. [DOI] [PubMed] [Google Scholar]
  • 136. Michikawa M (2003) Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease J Neurosci Res 72:141–146. [DOI] [PubMed] [Google Scholar]
  • 137. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K (2001) A novel action of alzheimer's amyloid beta‐protein (Abeta): oligomeric Abeta promotes lipid release. J Neurosci 21:7226–7235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138. Misonou H, Morishima‐Kawashima M, Ihara Y (2000) Oxidative stress induces intracellular accumulation of amyloid beta‐protein (Abeta) in human neuroblastoma cells. Biochemistry 39:6951–6959. [DOI] [PubMed] [Google Scholar]
  • 139. Miura T, Suzuki K, Kohata N, Takeuchi H (2000) Metal binding modes of Alzheimer's amyloid beta‐peptide in insoluble aggregates and soluble complexes. Biochemistry 39:7024–7031. [DOI] [PubMed] [Google Scholar]
  • 140. Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C, Yanagisawa K (1999) Cholesterol‐dependent generation of a seeding amyloid beta‐protein in cell culture. J Biol Chem 274:15110–15114. [DOI] [PubMed] [Google Scholar]
  • 141. Moir RD, Atwood CS, Romano DM, Laurans MH, Huang X, Bush AI, Smith JD, Tanzi RE (1999) Differential effects of apolipoprotein E isoforms on metal‐induced aggregation of A beta using physiological concentrations. Biochemistry 38:4595–4603. [DOI] [PubMed] [Google Scholar]
  • 142. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD (1999) Increased CSF F2‐isoprostane concentration in probable AD. Neurology 52:562–565. [DOI] [PubMed] [Google Scholar]
  • 143. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, Mullan MJ (2001) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 60:778–785. [DOI] [PubMed] [Google Scholar]
  • 144. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Hough G, Wagner A, Nakamura K, Garber DW, Datta G, Segrest JP, Hama S, Fogel‐man AM (2003) Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr Opin Investig Drugs 4:1100–1104. [PubMed] [Google Scholar]
  • 145. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM (2004) The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45:993–1007. [DOI] [PubMed] [Google Scholar]
  • 146. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM (2001) HDL and the inflammatory response induced by LDL‐derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481–488. [DOI] [PubMed] [Google Scholar]
  • 147. Navab M, Hama S, Hough G, Fogelman AM (2003) Oral synthetic phospholipid (DMPC) raises high‐density lipoprotein cholesterol levels, improves high‐density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E‐null mice. Circulation 108:1735–1739. [DOI] [PubMed] [Google Scholar]
  • 148. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA (1999) Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 893:362–364. [DOI] [PubMed] [Google Scholar]
  • 149. Nunomura A, Perry G, Pappolla MA, Fried‐land RP, Hirai K, Chiba S, Smith MA (2000) Neuronal oxidative stress precedes amyloid‐beta deposition in Down syndrome. J Neuropathol Exp Neurol 59:1011–1017. [DOI] [PubMed] [Google Scholar]
  • 150. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease. Neuron 41:27–33. [DOI] [PubMed] [Google Scholar]
  • 151. Olesen OF, Dago L (2000) High density lipoprotein inhibits assembly of amyloid beta‐peptides into fibrils. Biochem Biophys Res Commun 270:62–66. [DOI] [PubMed] [Google Scholar]
  • 152. Olivieri G, Baysang G, Meier F, Muller‐Spahn F, Stahelin HB, Brockhaus M, Brack C (2001) N‐acetyl‐L‐cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta‐amyloid secretion and tau phosphorylation. J Neurochem 76:224–233. [DOI] [PubMed] [Google Scholar]
  • 153. Olivieri G, Brack C, Muller‐Spahn F, Stahelin HB, Herrmann M, Renard P, Brockhaus M, Hock C (2000) Mercury induces cell cytotoxicity and oxidative stress and increases beta‐amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem 74:231–236. [DOI] [PubMed] [Google Scholar]
  • 154. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46–54. [DOI] [PubMed] [Google Scholar]
  • 155. Perry G, Nunomura A, Raina AK, Smith MA (2000) Amyloid‐beta junkies. Lancet 355:757. [DOI] [PubMed] [Google Scholar]
  • 156. Pfrieger FW (2003) Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes Bioessays 25:72–78. [DOI] [PubMed] [Google Scholar]
  • 157. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH (1987) Lipoproteins and their receptors in the central nervous system. J Biol Chem 262:14352–14360. [PubMed] [Google Scholar]
  • 158. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21:4183–4187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159. Pratico DVMYL, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12:1777–1783. [DOI] [PubMed] [Google Scholar]
  • 160. Raby CA, Morganti‐Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Roher AE, Emmerling MR (1998) Traumatic brain injury increases beta‐amyloid peptide 1–42 in cerebrospinal fluid. J Neurochem 71:2505–2509. [DOI] [PubMed] [Google Scholar]
  • 161. Rebeck GW, Alonzo NC, Berezovska O, Harr SD, Knowles RB, Growdon JH, Hyman BT, Mendez AJ (1998) Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp Neurol 149:175–182. 9454626 [Google Scholar]
  • 162. Robinson SR, Bishop GM, Lee HG, Munch G (2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25:609–615. [DOI] [PubMed] [Google Scholar]
  • 163. Roheim PS, Carey M, Forte T, Vega GL (1979) Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A 76:4646–4649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164. Rosenson RS (2003) Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 171:87–96. [DOI] [PubMed] [Google Scholar]
  • 165. Rottkamp CA, Atwood CS, Joseph JA, Nunomura A, Perry G, Smith MA (2002) The state versus amyloid‐beta: the trial of the most wanted criminal in Alzheimer disease. Peptides 23:1333–1341. [DOI] [PubMed] [Google Scholar]
  • 166. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA (2001) Redox‐active iron mediates amyloid‐beta toxicity. Free Radic Biol Med 30:447–450. [DOI] [PubMed] [Google Scholar]
  • 167. Salvayre R, Auge N, Benoist H, Negre‐Salvayre A (2002) Oxidized low‐density lipoprotein‐induced apoptosis. Biochim Biophys Acta 1585:213–221. [DOI] [PubMed] [Google Scholar]
  • 168. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha‐to‐copherol, or both as treatment for Alzheimer's disease. N Engl J Med 336:1216–1222. [DOI] [PubMed] [Google Scholar]
  • 169. Sato M, Ohtomo K, Daimon T, Sugiyama T, Iijima K (1994) Localization of copper to afferent terminals in rat locus ceruleus, in contrast to mitochondrial copper in cerebellum. J Histochem Cytochem 42:1585–1591. [DOI] [PubMed] [Google Scholar]
  • 170. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74:270–279. [DOI] [PubMed] [Google Scholar]
  • 171. Schenk D, Hagen M, Seubert P (2004) Current progress in beta‐amyloid immunotherapy. Curr Opin Immunol 16:599–606. [DOI] [PubMed] [Google Scholar]
  • 172. Schenk DB, Seubert P, Lieberburg I, Wallace J (2000) Beta‐peptide immunization: a possible new treatment for Alzheimer disease. Arch Neurol 57:934–936. [DOI] [PubMed] [Google Scholar]
  • 173. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller‐Thomsen T, Beisiegel U (2000) Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 28:351–360. [DOI] [PubMed] [Google Scholar]
  • 174. Schippling S, Kontush A, Arlt S, Daher D, Buhmann C, Stürenburg HJ, Mann U, Müller‐Thomsen T, Beisiegel U (1999) Lipoprotein oxidation and Alzheimer's disease. In: Alzheimer's Disease and Related Disorders, Igbal K, Swaab DF, Winblad B, Wisniewski HM (eds.), pp. 471–477, John Wiley & Sons: New York . [Google Scholar]
  • 175. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741–766. [DOI] [PubMed] [Google Scholar]
  • 176. Selkoe DJ (1998) The cell biology of beta‐amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8:447–453. [DOI] [PubMed] [Google Scholar]
  • 177. Selkoe DJ, Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid‐based therapeutics. Annu Rev Pharmacol Toxicol 43:545–584. [DOI] [PubMed] [Google Scholar]
  • 178. Shie FS, Jin LW, Cook DG, Leverenz JB, Le‐Boeuf RC (2002) Diet‐induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13:455–459. [DOI] [PubMed] [Google Scholar]
  • 179. Smith MA, Atwood CS, Joseph JA, Perry G (2002) Predicting the failure of amyloid‐beta vaccine. Lancet 359:1864–1865. [DOI] [PubMed] [Google Scholar]
  • 180. Smith MA, Casadesus G, Joseph JA, Perry G (2002) Amyloid‐beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 33:1194–1199. [DOI] [PubMed] [Google Scholar]
  • 181. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox‐generated free radicals. Proc Natl Acad Sci U S A 94:9866–9868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182. Smith MA, Joseph JA, Atwood CS, Perry G (2002) Dangers of the amyloid‐beta vaccination. Acta Neuropathol (Berl) 104:110. [DOI] [PubMed] [Google Scholar]
  • 183. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G (2000) Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2:413–420. [DOI] [PubMed] [Google Scholar]
  • 184. Smith MA, Perry G (1998) What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease J Chem Neuroanat 16:35–41. [DOI] [PubMed] [Google Scholar]
  • 185. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502:139–144. [DOI] [PubMed] [Google Scholar]
  • 186. Song H, Saito K, Seishima M, Noma A, Urakami K, Nakashima K (1997) Cerebrospinal fluid apo E and apo A‐I concentrations in early‐and late‐onset Alzheimer's disease. Neurosci Lett 231:175–178. [DOI] [PubMed] [Google Scholar]
  • 187. Sparks DL, Martin TA, Gross DR, Hunsaker JC, 3rd (2000) Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech 50:287–290. [DOI] [PubMed] [Google Scholar]
  • 188. Sparks DL, Schreurs BG (2003) Trace amounts of copper in water induce beta‐amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 100:11065–11069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189. Sprecher DL (2000) Raising high‐density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol 86:46L–50L. [DOI] [PubMed] [Google Scholar]
  • 190. Srivastava RA, Jain JC (2002) Scavenger receptor class B type I expression and elemental analysis in cerebellum and parietal cortex regions of the Alzheimer's disease brain. J Neurol Sci 196:45–52. [DOI] [PubMed] [Google Scholar]
  • 191. Stocker R (1994) Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 5:422–433. [PubMed] [Google Scholar]
  • 192. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak‐Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform‐specific effects and implications for late‐onset Alzheimer disease. Proc Natl Acad Sci U S A 90:8098–8102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18:323–325. Epub 2003 Dec 2004. [DOI] [PubMed] [Google Scholar]
  • 194. Suzuki T, Tozuka M, Kazuyoshi Y, Sugano M, Nakabayashi T, Okumura N, Hidaka H, Katsuyama T, Higuchi K (2002) Predominant apolipoprotein J exists as lipid‐poor mixtures in cerebrospinal fluid. Ann Clin Lab Sci 32:369–376. [PubMed] [Google Scholar]
  • 195. Swerdlow RH, Khan SM (2004) A “mitochondrial cascade hypothesis” for sporadic Alzheimer's disease. Med Hypotheses 63:8–20. [DOI] [PubMed] [Google Scholar]
  • 196. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10:279–288. [DOI] [PubMed] [Google Scholar]
  • 197. Tuppo EE, Forman LJ, Spur BW, Chan‐Ting RE, Chopra A, Cavalieri TA (2001) Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54:565–568. [DOI] [PubMed] [Google Scholar]
  • 198. van Tol A (2002) Phospholipid transfer protein. Curr Opin Lipidol 13:135–139. [DOI] [PubMed] [Google Scholar]
  • 199. Van Uden E, Kang DE, Koo EH, Masliah E (2000) LDL receptor‐related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis. Microsc Res Tech 50:268–272. [DOI] [PubMed] [Google Scholar]
  • 200. Varadarajan S, Yatin S, Aksenova M, Butterfield DA (2000) Review: Alzheimer's amyloid beta‐peptide‐associated free radical oxidative stress and neurotoxicity. J Struct Biol 130:184–208. [DOI] [PubMed] [Google Scholar]
  • 201. Vassallo N, Herms J (2003) Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J Neurochem 86:538–544. [DOI] [PubMed] [Google Scholar]
  • 202. Vuletic S, Jin LW, Marcovina SM, Peskind ER, Moller T, Albers JJ (2003) Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res 44:1113–1123. Epub 2003 Apr 1111. [DOI] [PubMed] [Google Scholar]
  • 203. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM (2004) ABCA1 is required for normal CNS apoE levels and for lipidation of astrocyte‐secreted apoE. J Biol Chem 21:21. [DOI] [PubMed] [Google Scholar]
  • 204. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB (1999) Amyloid beta‐protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945–25952. [DOI] [PubMed] [Google Scholar]
  • 205. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11:213–228. [DOI] [PubMed] [Google Scholar]
  • 206. Walter MF, Mason PE, Mason RP (1997) Alzheimer's disease amyloid beta peptide 25–35 inhibits lipid peroxidation as a result of its membrane interactions. Biochem Biophys Res Commun 233:760–764. [DOI] [PubMed] [Google Scholar]
  • 207. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW (2004) Increased beta‐secretase activity and expression in rats following transient cerebral ischemia. Brain Res 1009:1–8. [DOI] [PubMed] [Google Scholar]
  • 208. Whitson JS, Glabe CG, Shintani E, Abcar A, Cotman CW (1990) Beta‐amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci Lett 110:319–324. [DOI] [PubMed] [Google Scholar]
  • 209. Whitson JS, Selkoe DJ, Cotman CW (1989) Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 243:1488–1490. [DOI] [PubMed] [Google Scholar]
  • 210. Wolfe MS, Kopan R (2004) Intramembrane proteolysis: theme and variations. Science 305:1119–1123. [DOI] [PubMed] [Google Scholar]
  • 211. Wolozin B, Brown J, 3rd , Theisler C, Silberman S (2004) The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 10:127–146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 212. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, al e (1995) Non‐enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta‐peptide. Nat Med 1:693–699. [DOI] [PubMed] [Google Scholar]
  • 213. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250:279–282. [DOI] [PubMed] [Google Scholar]
  • 214. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE (2001) Metallothionein III is reduced in Alzheimer's disease. Brain Res 894:37–45. [DOI] [PubMed] [Google Scholar]
  • 215. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh‐Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61:82–88. [DOI] [PubMed] [Google Scholar]
  • 216. Zhang L, Zhao B, Yew DT, Kusiak JW, Roth GS (1997) Processing of Alzheimer's amyloid precursor protein during H2O2‐ induced apoptosis in human neuronal cells. Biochem Biophys Res Commun 235:845–848. [DOI] [PubMed] [Google Scholar]
  • 217. Zou K, Gong JS, Yanagisawa K, Michikawa M (2002) A novel function of monomeric amyloid beta‐protein serving as an antioxidant molecule against metal‐induced oxidative damage. J Neurosci 22:4833–4841. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES